Philogen who? A low profile but pharma-connected Italian-Swiss hybrid steps out with $68M for a final push over the PhIII finish line

Philogen is one of the best connected late-stage biotechs you’ve probably never heard of.

Founded by three brothers — the businessman and company CEO Duccio Neri and his two scientist siblings, Dario and Giovanni — way back in 1996, Philogen has been building up its expertise in armed antibodies over the past 23 years.